Yuval Cohen, PhDChief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus in July 2013 as Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus successfully developed five novel anti-inflammatory drug programs - including two in Phase II - focusing on allergies and autoimmune diseases of the skin, airways, digestive tract and eye. He participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fund raising. In March 2013, Dr. Cohen successfully completed a public listing of Celsus in the United States. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. He attained a Bachelor of Science (Honors) from the University of Cape Town (South Africa) before being awarded the prestigious BGF Scholarship from the French foreign ministry to carry out his doctoral studies in Paris.
Mark A. Tepper, PhDPresident & Chief Scientific Officer
Mark A. Tepper, Ph.D., co-founded the Company in 2009. He has more than twenty years of leadership experience in pharmaceutical R&D and his past roles include leadership positions at Bristol Myers Squibb, Serono, CytRx, RXi Pharmaceuticals and NKT Therapeutics. Dr. Tepper has led teams in the discovery and development of a number of first-in-class drugs, including Guspermis, Taxol, Rebif, Orcenia and Gonal-F. During the last 10 years Dr. Tepper has focused his career on identifying unique early stage biotechnology assets, which fill a significant unmet medical need and forming companies to commercialize these assets. In this role, he has successfully founded and developed the commercialization strategy for 3 new biotech companies, raising over $45M in funding. Dr. Tepper received a Ph.D. in Biochemistry & Biophysics from Columbia University, College of Physicians & Surgeons, New York, and a B.A. in Chemistry with Highest Honors from Clark University, Worcester, Mass. He gained postdoctoral training at the University of Massachusetts Medical School, Worcester, MA in the laboratory of Professor Michael P. Czech.
Barbara White, MDChief Medical Officer
Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industry experience in pre-clinical drug development, translational medicine and medical affairs. Prior to joining Corbus, Dr. White was Senior Vice President and Head of R&D at Stiefel, a GSK company. She has held roles at UCB, MedImmune and Amgen. Prior to her pharmaceutical career, Dr. White was professor of medicine and Vice Chair for Research, Department of Medicine, at the University of Maryland School of Medicine. Her research has focused on T cells and immune-mediated mechanisms of lung fibrosis in scleroderma. She also previously served as co-director of the Johns Hopkins University and University of Maryland Scleroderma Center. Dr. White received her medical degree from the University of Pennsylvania School of Medicine and is board certified in internal medicine, rheumatology and allergy/clinical immunology. She completed her postdoctoral studies in basic cellular immunology at the National Institutes of Health.
Sean Moran, CPA, MBAChief Financial Officer
Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has successfully managed operations from start up through development to commercialization and profitability. He has completed three IPOs and has raised over $200 million of capital. Before joining Corbus, Mr. Moran served as Chief Financial Officer for InVivo Therapeutics, Celsion Corporation, Echo Therapeutics, and Anika Therapeutics. Mr. Moran is a CPA and MBA by training having earned his M.B.A. and a B.S. in Accounting from Babson College.
Robert Discordia, Ph.D.Vice President, Pharmaceutical Development & Manufacturing
Robert Discordia, Ph.D., joined Corbus as Vice President, Pharmaceutical Development & Manufacturing in May 2018. Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and business operations. Prior to joining the Company, Dr. Discordia was Executive Director, Business Operations, Procurement for Global Product Development & Supply at Bristol-Myers Squibb. While serving in that position, he was responsible for managing the strategic business partnerships for the company’s small molecule development and commercial manufacturing. He oversaw approximately 55 employees at seven sites and $700 million in annual spend. Prior to that, he served as Bristol-Myers Squibb’s Group Director & Head, External Partner Management, Pharmaceutical Development. In this capacity, he developed and led the organization, overseeing third-party providers of development services and clinical manufacturing for Bristol-Myers Squibb. Over his career, he had leadership roles in the CMC development and launch of multiple medicines, including TAXOL®, BARACLUDE® and ELIQUIS®. He currently serves on the Advisory Board for the Drug, Chemical & Associated Technologies Association (DCAT) and is a member of the Outsourced Pharma Editorial Advisory Board. Dr. Discordia received his Ph.D. in Organic Chemistry from Syracuse University and a Bachelor of Science in Chemistry from SUNY Cortland. He completed his postdoctoral training at The Research Institute of Scripps Clinic and the University of California, San Diego in the laboratory of Professor K. C. Nicolaou.
Ross LobellVice President, Regulatory Affairs
Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations to support the drug development process. Prior to his appointment at Corbus, he held various leadership positions across several global pharmaceutical companies, including Schering-Plough, Pfizer, Amgen and MedImmune, a member of the AstraZeneca Group. During his tenure at MedImmune, Mr. Lobell oversaw all regulatory affairs support for the Respiratory, Inflammation and Anti-inflammatory biologics programs. Over the course of his career, Mr. Lobell led development, registration and post-registration activities for small-molecule and biologic medicines in multiple therapeutic areas, including oncology, rheumatology, respiratory, women’s health and cardiology/lipid metabolism. Additionally, he oversaw the development, submission and review management process for New Drug Applications, Biologics License Applications, and supplemental efficacy applications to expand labeling. Mr. Lobell received his Bachelor of Science in Biology from Lebanon Valley College.